Status:
COMPLETED
Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery
Lead Sponsor:
Region Skane
Conditions:
Kidney Failure
Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.
Detailed Description
Acute kidney injury is a common complication after cardiac surgery and is associated with decreased long-term survival. Several experimental and animal studies have showed cytoprotective, preconditio...
Eligibility Criteria
Inclusion
- The patient is scheduled for non-emergent CABG surgery.
- CyC eGFR or MDRD eGFR \< 60 ml/min.
- The patient has given his/her written consent to participate
Exclusion
- The patient has an uncontrolled hypertension.
- Hypersensitivity to the active drug.
- The patient is pregnant or is a fertile woman (\<50 years).
- The patient has been treated with Erythropoietin within 4 weeks prior to the surgery.
- Preoperative CyC eGFR or MDRD eGFR is \< 15, or the patient is treated with dialysis.
- The patient has a known malignancy.
- The patient is planned for Off-pump CABG surgery.
- The patient is included in other ongoing clinical trial. Yes / No
- Clinically judgment by the investigator that the patient should not participate in the study.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01423955
Start Date
October 1 2011
End Date
April 1 2013
Last Update
October 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept Thoracic Surgery, Anestesia and Intensive Care, SUS-Lund
Lund, Sweden, 221 85